Bharat Biotech’s Covaxin is safe for the short term, says Lancet on preliminary data

Data from Phase 3 trials of the coronavirus vaccine Covaxin, developed in India, has shown that two doses offer 77.8% protection against COVID-19, according to findings published Thursday in The Lancet medical journal.

Covaxin, known by the code BBV152, is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology.

The drug on Nov. 3 was granted emergency use approval by the World Health Organization (WHO) for adults 18 years and older and is the eighth jab to be given the green light by the health body.

The WHO determined that Covaxin met its standards for protection against COVID-19 and “that the benefit of the vaccine far outweighs risks.”

It recommended the vaccine be administered in two doses, with an interval of four weeks in age groups 18 and above.

The jab has not been advised for pregnant women as available data is “insufficient” to “assess vaccine safety or efficacy in pregnancy.”

Other COVID-19 vaccines approved by the specialized UN agency are Pfizer-BioNTech, Oxford-AstraZeneca, Johnson & Johnson’s Janssen, Moderna, Sinopharm, and Sinovac.

The Phase 3 trials ran from Nov. 16, 2020, until May 17, 2021, and included participants between 18 and 97 years old, said the article in the scientific journal.

Trial participants were given two doses of either Covaxin or a placebo.

Participants considered at high risk for COVID-19 infection were prioritized, with 2,750 participants above 60 years of age and 5,724 participants with at least one preexisting condition included in the study.

Participants were recruited from 25 hospitals across India for geographic diversity.

Covaxin “was well-tolerated by all trial participants; 12% of both groups reported an adverse event, with no significant difference in the number of events between the placebo and BBV152 groups,” said the findings.

Latest

LCA Tejas gets equipped with JDAM-ER precision Bomb Kits

The indigenous LCA Tejas fighter jets are to be...

A nuclear attack won’t stop Sarmat ICBM from launching

Vladimir Degtyar, the general designer of the Makeev State...

Airbus pushes its five-bladed H145M helicopter to the German army

Airbus Helicopters took advantage of the ILA show in...

M777 howitzers constantly break down and require repair, says Ukraine

After complaining about insufficient and obsolete weapons being supplied...

Newsletter

spot_img

From Same Category

Japan is developing a vaccine that gives permanent immunity to COVID-19

In Japan, a vaccine against COVID-19 is in development,...

Pfizer anti-Covid pill Paxlovid: how and when to use it

The U.S. has given the green light for Pfizer's...

Novavax protein vaccine: how it works, side effects of the COVID-19 jab

A protein vaccine differs from the mRNA vaccines (Pfizer...

Another foreign made COVID vaccine, ‘Covovax’, gained WHO approval

WHO has made a written statement regarding the use...

All you want to know about the South African coronavirus variant is called Omicron

WHO has designated the new variant of SARS-CoV-2 detected...
Frontier India News Network
Frontier India News Network
Frontier India News Network is the in-house news collection and distribution agency.
spot_imgspot_img

LCA Tejas gets equipped with JDAM-ER precision Bomb Kits

The indigenous LCA Tejas fighter jets are to be equipped with Joint Direct Attack Munition Extended Range (JDAM-ER) precision-guided bombing kits which will enable...

A nuclear attack won’t stop Sarmat ICBM from launching

Vladimir Degtyar, the general designer of the Makeev State Missile Center, said that the silo launchers for Sarmats should guarantee their safety, including when...

Airbus pushes its five-bladed H145M helicopter to the German army

Airbus Helicopters took advantage of the ILA show in Berlin to announce that it had joined forces with a team of industrialists to offer...

LEAVE A REPLY

Please enter your comment!
Please enter your name here